CF
VTGN icon

Centaurus Financial’s VistaGen Therapeutics VTGN Stock Holding History

Centaurus Financial’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-337
Closed -$28K – 983
2021
Q3 		$28K Hold
337
– – ﹤0.01% 882
2021
Q2 		$32K Buy
337
+4
+1% +$296 ﹤0.01% 887
2021
Q1 		$21K Buy
+333
New +$22.2K ﹤0.01% 810

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

Centaurus Financial's VTGN Position: Q4 2021 in Review

Centaurus Financial sold out of VistaGen Therapeutics (VTGN) in Q4 2021, closing a stake of 337 shares — an estimated $28K sold.

Centaurus Financial first reported a position in VTGN in Q1 2021 and held it in 3 quarters. The position peaked at $32K in Q2 2021. 106 funds tracked by Wall St. Rank hold VTGN as of Q4 2021.

  • Centaurus Financial reported no remaining VistaGen Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Centaurus Financial sold 337 VistaGen Therapeutics shares in Q4 2021, an estimated $28K.
  • Centaurus Financial first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 3 quarters.
  • Centaurus Financial's VistaGen Therapeutics position peaked at $32K in Q2 2021.
  • 106 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2021.

Based on Centaurus Financial's 13F filing for Q4 2021, filed 1 Feb 2022.